@article {Skalafouris113, author = {Christian Skalafouris and Caroline Samer and Jerome Stirnemann and Olivier Grosgurin and Fran{\c c}ois Eggimann and Damien Grauser and Jean-Luc Reny and Pascal Bonnabry and Bertrand Guignard}, title = {Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19}, volume = {30}, number = {2}, pages = {113--116}, year = {2023}, doi = {10.1136/ejhpharm-2020-002667}, publisher = {BMJ Specialist Journals}, abstract = {During Switzerland{\textquoteright}s first wave of COVID-19, clinical pharmacy activities during medical rounds in Geneva University Hospitals were replaced by targeted remote interventions. We describe using the electronic PharmaCheck system to screen high-risk situations of adverse drug events (ADEs), particularly targeting prescriptions of lopinavir/ritonavir (LPVr) and hydroxychloroquine (HCQ) in the presence of contraindications or prescriptions outside institutional guidelines. Of 416 patients receiving LPVr and/or HCQ, 182 alerts were triggered for 164 (39.4\%) patients. The main associated risk factors of ADEs were drug{\textendash}drug interactions, QTc interval prolongation, electrolyte disorder and inadequate LPVr dosage. Therapeutic optimisation recommended by a pharmacist or proposals for additional monitoring were accepted in 80\% (n=36) of cases. Combined with pharmacist contextualisation to the clinical context, PharmaCheck made it possible to successfully adapt clinical pharmacist activities by switching from a global to a targeted analysis mode in an emergency context.All data relevant to the study are included in the article or uploaded as supplementary information.}, issn = {2047-9956}, URL = {https://ejhp.bmj.com/content/30/2/113}, eprint = {https://ejhp.bmj.com/content/30/2/113.full.pdf}, journal = {European Journal of Hospital Pharmacy} }